Thank you for requesting A Review of the Global Biopharmaceutical Royalty Rates and Deal Terms Survey - les Nouvelles.
To download a copy of this document, please provide the following basic information:
Licensing professionals often seek deal term and royalty rate benchmarks. Such information can often be found in subscriber access databases, which provide a valuable service by consolidating information provided in public disclosures of important deals. A primary input is data obtained on public companies from information filed with the US Securities and Exchange Commission (SEC) and accessed either through a review of mandatory public disclosures or gained through Freedom of Information Act (FOIA) requests. However, the FOIA approach has significant limitations for deal information related to academic deals, deals by private companies (especially biotech deals), and deals outside the US. The Licensing Executives Society (USA and Canada), Inc., has recognized a need for a more robust dataset to address aspects of this information gap. To fill this void, the organization periodically surveys its members to gather information on the deal term and royalty rate environment. This article summarizes results from the most recent survey. 